Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease

Background  One‐third of patients with inflammatory bowel disease (IBD) receiving azathioprine (AZA) withdraw treatment due to side effects or lack of clinical response.

[1]  J. Gisbert,et al.  Comparative effectiveness of azathioprine in Crohn’s disease and ulcerative colitis: prospective, long‐term, follow‐up study of 394 patients , 2008, Alimentary pharmacology & therapeutics.

[2]  I. Bruce,et al.  TPMT testing in rheumatology: any better than routine monitoring? , 2007, Rheumatology.

[3]  S. Hanauer,et al.  Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[4]  J. Gisbert,et al.  Thiopurine Methyltransferase (TPMT) Activity and Adverse Effects of Azathioprine in Inflammatory Bowel Disease: Long-Term Follow-Up Study of 394 Patients , 2006, The American Journal of Gastroenterology.

[5]  M. Heneghan,et al.  Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitis. , 2006, Journal of hepatology.

[6]  R. Gearry,et al.  Two cases of thiopurine methyltransferase (TPMT) deficiency--a lucky save and a near miss with azathioprine. , 2006, British journal of clinical pharmacology.

[7]  R. Ashcroft,et al.  Genetic databases and pharmacogenetics: introduction. , 2006, Studies in history and philosophy of biological and biomedical sciences.

[8]  A. Hedgecoe.  It's money that matters: the financial context of ethical decision-making in modern biomedicine. , 2006, Sociology of health & illness.

[9]  H Hildebrand,et al.  Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease , 2006, Alimentary pharmacology & therapeutics.

[10]  M. Benninga,et al.  Pharmacogenetics of thiopurine therapy in paediatric IBD patients , 2006, Alimentary pharmacology & therapeutics.

[11]  J. Lewis,et al.  Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. , 2006, Gastroenterology.

[12]  J. Sanderson,et al.  Typing TPMT and ITPase to detect azathioprine toxicity. , 2006, Personalized medicine.

[13]  V. Armstrong,et al.  Association of inosine triphosphatase 94C>A and thiopurine S-methyltransferase deficiency with adverse events and study drop-outs under azathioprine therapy in a prospective Crohn disease study. , 2005, Clinical chemistry.

[14]  E. Kuipers,et al.  ITPA genotyping is not predictive for the development of side effects in AZA treated inflammatory bowel disease patients. , 2005, Gut.

[15]  M. Dubinsky,et al.  A Cost-Effectiveness Analysis of Alternative Disease Management Strategies in Patients with Crohn's Disease Treated with Azathioprine or 6-Mercaptopurine , 2005, The American Journal of Gastroenterology.

[16]  Y. Lacasse,et al.  From the authors , 2005, European Respiratory Journal.

[17]  P. Hayes,et al.  Pharmacogenetic association with adverse drug reactions to azathioprine immunosuppressive therapy following liver transplantation , 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[18]  T. Kitiyakara,et al.  Cost‐effectiveness of thiopurine methyltransferase genotype screening in IBD , 2005, Alimentary pharmacology & therapeutics.

[19]  L. Beaugerie,et al.  Impact of the increasing use of immunosuppressants in Crohn’s disease on the need for intestinal surgery , 2005, Gut.

[20]  R. Gearry,et al.  Lack of association between the ITPA 94C>A polymorphism and adverse effects from azathioprine. , 2004, Pharmacogenetics.

[21]  J. Duley,et al.  Allele Frequency of Inosine Triphosphate Pyrophosphatase Gene Polymorphisms in a Japanese Population , 2004, Nucleosides, nucleotides & nucleic acids.

[22]  D. Gaffney,et al.  Cost‐effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease , 2004, Alimentary pharmacology & therapeutics.

[23]  H. Ogata,et al.  [A systematic review of the clinical effectiveness of azathioprine in patients with ulcerative colitis]. , 2004, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.

[24]  Jeremy Sanderson,et al.  Thiopurine methyltransferase: should it be measured before commencing thiopurine drug therapy? , 2004, Annals of clinical biochemistry.

[25]  Richard E Thompson,et al.  Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[26]  C. Lewis,et al.  Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). , 2004, Pharmacogenetics.

[27]  J. Lilleyman,et al.  Thiopurine drugs in the treatment of childhood leukaemia: the influence of inherited thiopurine methyltransferase activity on drug metabolism and cytotoxicity. , 2003, British journal of clinical pharmacology.

[28]  B. Korelitz,et al.  Cumulative Experience With Short- and Long-Term Toxicity to 6-Mercaptopurine in the Treatment of Crohn's Disease and Ulcerative Colitis , 2003, Journal of clinical gastroenterology.

[29]  S. Targan,et al.  Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine , 2003, American Journal of Gastroenterology.

[30]  V. Armstrong,et al.  Differences in nucleotide hydrolysis contribute to the differences between erythrocyte 6-thioguanine nucleotide concentrations determined by two widely used methods. , 2003, Clinical chemistry.

[31]  E. Louis,et al.  Safe treatment of thiopurine S-methyltransferase deficient Crohn’s disease patients with azathioprine , 2003, Gut.

[32]  J. Esdaile,et al.  Practical pharmacogenetics: the cost effectiveness of screening for thiopurine s-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine. , 2002, The Journal of rheumatology.

[33]  J. Sanderson,et al.  Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency , 2002, Human Genetics.

[34]  C Hassan,et al.  Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease , 2002, Alimentary pharmacology & therapeutics.

[35]  J. Sanderson,et al.  Erythrocyte thiopurine methyl transferase assessment prior to azathioprine use in the UK. , 2002, QJM : monthly journal of the Association of Physicians.

[36]  T. Bayless,et al.  Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease , 2001, Gut.

[37]  M. Relling,et al.  Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  B. Bonaz,et al.  Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. , 2000, Gastroenterology.

[39]  N. Shear,et al.  Screening for azathioprine toxicity: a pharmacoeconomic analysis based on a target case. , 2000, Journal of the American Academy of Dermatology.

[40]  S. Targan,et al.  Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. , 2000, Gastroenterology.

[41]  M. Relling,et al.  Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. , 1999, Journal of the National Cancer Institute.

[42]  G. Fick,et al.  Azathioprine for maintaining remission of Crohn's disease. , 1998, The Cochrane database of systematic reviews.

[43]  R. Boulieu,et al.  Simultaneous determination of 6-thioguanine and methyl 6-mercaptopurine nucleotides of azathioprine in red blood cells by HPLC. , 1998, Clinical chemistry.

[44]  R. Weinshilboum,et al.  Pharmacokinetics, dose adjustments, and 6‐mercaptopurine/ methotrexate drug interactions in two patients with thiopurine methyltransferase deficiency , 1998, Acta paediatrica.

[45]  J. Lilleyman,et al.  Individualizing therapy with 6-mercaptopurine and 6-thioguanine related to the thiopurine methyltransferase genetic polymorphism. , 1996, Therapeutic drug monitoring.

[46]  J. Lilleyman,et al.  Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia. , 1993, Archives of disease in childhood.

[47]  J. Kirby,et al.  Pancytopenia Related to Azathioprine — An Enzyme Deficiency Caused by a Common Genetic Polymorphism: A Review , 1992, Journal of the Royal Society of Medicine.

[48]  H. Simmonds,et al.  THE IMPORTANCE OF THIOPURINE METHYLTRANSFERASE ACTIVITY FOR THE USE OF AZATHIOPRINE IN TRANSPLANT RECIPIENTS1 , 1992, Transplantation.

[49]  W. Evans,et al.  Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. , 1991, The Journal of pediatrics.

[50]  S. Meltzer,et al.  6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. , 1989, Annals of internal medicine.

[51]  R. Weinshilboum,et al.  Pharmacogenetics of acute azathioprine toxicity: Relationship to thiopurine methyltransferase genetic polymorphism , 1989, Clinical pharmacology and therapeutics.

[52]  R. Weinshilboum,et al.  Thiopurine pharmacogenetics in leukemia: Correlation of erythrocyte thiopurine methyltransferase activity and 6‐thioguanine nucleotide concentrations , 1987, Clinical pharmacology and therapeutics.

[53]  D. Hommes,et al.  Inosine triphosphate pyrophosphatase and thiopurine s-methyltransferase genotypes relationship to azathioprine-induced myelosuppression. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[54]  R. Modigliani,et al.  Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. , 2000, The Cochrane database of systematic reviews.

[55]  J. Stobaugh,et al.  Determination of intracellular levels of 6-mercaptopurine metabolites in erythrocytes utilizing capillary electrophoresis with laser-induced fluorescence detection. , 1995, Analytical biochemistry.

[56]  L. Lennard,et al.  Assay of 6-thioinosinic acid and 6-thioguanine nucleotides, active metabolites of 6-mercaptopurine, in human red blood cells. , 1987, Journal of chromatography.